Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

2.

Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.

Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT.

Mult Scler. 2018 Sep;24(10):1347-1355. doi: 10.1177/1352458517721357. Epub 2017 Aug 2.

PMID:
28766993
3.

Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis.

Reider N, Salter AR, Cutter GR, Tyry T, Marrie RA.

Res Nurs Health. 2017 Apr;40(2):143-152. doi: 10.1002/nur.21783. Epub 2017 Feb 6.

PMID:
28165143
4.

Assessment of Caregiver Inventory for Rett Syndrome.

Lane JB, Salter AR, Jones NE, Cutter G, Horrigan J, Skinner SA, Kaufmann WE, Glaze DG, Neul JL, Percy AK.

J Autism Dev Disord. 2017 Apr;47(4):1102-1112. doi: 10.1007/s10803-017-3034-3.

5.
6.

Health insurance affects the use of disease-modifying therapy in multiple sclerosis.

Wang G, Marrie RA, Salter AR, Fox R, Cofield SS, Tyry T, Cutter GR.

Neurology. 2016 Jul 26;87(4):365-74. doi: 10.1212/WNL.0000000000002887. Epub 2016 Jun 29.

7.

Symptomatic Management of Multiple Sclerosis-Associated Tremor Among Participants in the NARCOMS Registry.

Meador W, Salter AR, Rinker JR 2nd.

Int J MS Care. 2016 May-Jun;18(3):147-53. doi: 10.7224/1537-2073.2015-008.

8.

Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.

Liu Y, Morgan C, Hornung L, Tyry T, Salter AR, Agashivala N, Belletti DA, Kim E, Fox RJ, Cofield SS, Cutter GR.

J Neurol Sci. 2016 Mar 15;362:121-6. doi: 10.1016/j.jns.2016.01.034. Epub 2016 Jan 19.

PMID:
26944131
9.

Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.

Fox RJ, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Kister I.

Neurodegener Dis Manag. 2015;5(6 Suppl):3-10. doi: 10.2217/nmt.15.55. Erratum in: Neurodegener Dis Manag. 2016;6(2):178.

10.

Causes of death among persons with multiple sclerosis.

Cutter GR, Zimmerman J, Salter AR, Knappertz V, Suarez G, Waterbor J, Howard VJ, Marrie RA.

Mult Scler Relat Disord. 2015 Sep;4(5):484-490. doi: 10.1016/j.msard.2015.07.008. Epub 2015 Jul 18.

PMID:
26346799
11.

Impact of multiple sclerosis relapse: The NARCOMS participant perspective.

Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA.

Mult Scler Relat Disord. 2015 May;4(3):234-40. doi: 10.1016/j.msard.2015.03.005. Epub 2015 Mar 27.

12.

Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab.

Rinker JR 2nd, Salter AR, Cutter GR.

Mult Scler Relat Disord. 2014 Jul;3(4):505-12. doi: 10.1016/j.msard.2014.04.001. Epub 2014 Apr 8.

PMID:
25877063
13.

Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey.

Rinker JR 2nd, Salter AR, Walker H, Amara A, Meador W, Cutter GR.

BMJ Open. 2015 Jan 8;5(1):e006714. doi: 10.1136/bmjopen-2014-006714.

14.

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry.

Salter AR, Marrie RA, Agashivala N, Belletti DA, Kim E, Cutter GR, Cofield SS, Tyry T.

Patient Prefer Adherence. 2014 Jul 4;8:971-9. doi: 10.2147/PPA.S49903. eCollection 2014.

15.

Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.

Fox RJ, Salter AR, Tyry T, Sun J, You X, Laforet G, Campagnolo D.

Int J MS Care. 2013 Winter;15(4):194-201. doi: 10.7224/1537-2073.2012-034.

16.

Natural history of multiple sclerosis symptoms.

Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J.

Int J MS Care. 2013 Fall;15(3):146-58. doi: 10.7224/1537-2073.2012-053. Erratum in: Int J MS Care. 2014 Winter;16(4):170.

17.

Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought.

Marrie RA, Salter AR, Tyry T, Fox RJ, Cutter GR.

J Med Internet Res. 2013 Mar 17;15(4):e67. doi: 10.2196/jmir.2466.

18.

Disability in multiple sclerosis: a reference for patients and clinicians.

Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J.

Neurology. 2013 Mar 12;80(11):1018-24. doi: 10.1212/WNL.0b013e3182872855. Epub 2013 Feb 20.

19.

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS; CombiRx Investigators.

Ann Neurol. 2013 Mar;73(3):327-40. doi: 10.1002/ana.23863. Epub 2013 Mar 11.

20.

"Seeing" in NARCOMS: a look at vision-related quality of life in the NARCOMS registry.

Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA.

Mult Scler. 2013 Jun;19(7):953-60. doi: 10.1177/1352458512469694. Epub 2012 Dec 20.

PMID:
23257618
21.

Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS.

Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T.

Curr Med Res Opin. 2010 Feb;26(2):493-500. doi: 10.1185/03007990903500649.

PMID:
20014979
22.

Retinal architecture predicts pupillary reflex metrics in MS.

Salter AR, Conger A, Frohman TC, Zivadinov R, Eggenberger E, Calabresi P, Cutter G, Balcer L, Frohman EM.

Mult Scler. 2009 Apr;15(4):479-86. doi: 10.1177/1352458508100503. Epub 2008 Dec 17.

PMID:
19091882
23.

Break in binocular fusion during head turning in MS patients with INO.

Mills DA, Frohman TC, Davis SL, Salter AR, McClure S, Beatty I, Shah A, Galetta S, Eggenberger E, Zee DS, Frohman EM.

Neurology. 2008 Aug 5;71(6):458-60. doi: 10.1212/01.wnl.0000324423.08538.dd. No abstract available.

PMID:
18678831

Supplemental Content

Loading ...
Support Center